Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of depemokimab added early in eosinophilic COPD with type 2 inflammation
MOH_2026-01-18_015607Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Depemokimab add-on with Placebo add-on (2 arms). Primary endpoint: Efficacy of depemokimab versus placebo. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
depemokimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on MOH_2026-01-18_015607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-01-18_015607.